Nektar Therapeutics
A biopharmaceutical company that uses a technology called PEGylation—attaching polymer chains to drugs so they dissolve better and last longer in the body—and now focuses on therapies for immune and inflammatory diseases. It began in 1990 as Inhale Therapeutic Systems, a firm known for inhaled drug delivery, and took the name Nektar in 2003 to signal a broader mission. The name plays on "nectar," a sweet nod for a company whose famous early product was the inhaled insulin Exubera.
Sold 56.0K
Granted 103.8K · Sold 46.3K
Granted 883.6K · Sold 586.3K
Granted 1.54M · Sold 1.28M
Granted 313.6K · Bought 15.0K · Sold 65.0K
Granted 290.3K · Bought 40.0K · Sold 42.5K
Granted 431.4K · Sold 373.3K
Granted 266.4K · Sold 43.1K
Granted 53.1K · Sold 43.5K
Granted 995.3K · Sold 839.5K
Granted 823.2K · Bought 15.0K · Sold 727.8K
Granted 366.1K · Sold 254.0K
Granted 82.0K
Granted 107.0K · Bought 5.0K · Sold 64.3K
Granted 257.5K · Sold 208.4K
Granted 5.62M · Bought 10.0K · Sold 4.56M
Granted 196.8K · Sold 151.5K
Granted 249.8K · Sold 215.5K
Granted 63.3K · Sold 29.1K
Granted 28.6K
Granted 20.4K · Sold 12.2K
Granted 44.5K · Sold 21.3K
Granted 425.6K · Sold 169.6K
Granted 135.0K · Sold 115.0K
Granted 29.9K · Sold 1.6K
Granted 551.1K · Sold 456.2K
Granted 10.3K · Sold 5.2K
Granted 15.0K
Granted 10.0K
Granted 1.1K
Granted 6.5K
Granted 1.0K · Bought 5.0K
Granted 1.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kroin David +2 co-filers10% owner · 1 transaction | — | 18.34Mas of May 2024 | — | — | 56.0K |
| Patton John StuartChief Scientific Officer, Director · 18 transactions | — | 313.9Kas of Nov 2008 | 103.8K | — | 46.3K |
| Thomsen Jillian B.Chief Financial Officer · 79 transactions | — | 313.5Kas of Feb 2023 | 883.6K | — | 586.3K |
| Labrucherie Gil MSVP, COO & CFO · 113 transactions | — | 312.9Kas of May 2022 | 1.54M | — | 1.28M |
| Greer R ScottDirector · 27 transactions | — | 303.6Kas of Sep 2022 | 313.6K | 15.0K | 65.0K |
| Whitfield Roy ADirector · 31 transactions | — | 287.8Kas of Jun 2023 | 290.3K | 40.0K | 42.5K |
| Chess RobertDirector · 87 transactions | — | 259.5Kas of Jun 2024 | 431.4K | — | 373.3K |
| Northcott JohnSVP & Chief Commercial Officer · 9 transactions | — | 223.2Kas of May 2022 | 266.4K | — | 43.1K |
| Gill AjitPresident & CEO, Former Director, Pres. & CEO · 17 transactions | — | 170.8Kas of Mar 2006 | 53.1K | — | 43.5K |
| Nicholson JohnSVP & Chief Operating Officer · 48 transactions | — | 162.8Kas of Aug 2019 | 995.3K | — | 839.5K |
| Doberstein Stephen KSVP & Chief Scientific Officer · 40 transactions | — | 107.7Kas of Sep 2019 | 823.2K | 15.0K | 727.8K |
| Hora ManinderSVP Pharma Dev & Mfg Ops · 36 transactions | — | 94.7Kas of May 2019 | 366.1K | — | 254.0K |
| Krivulka Joseph JDirector · 8 transactions | — | 82.0Kas of Sep 2017 | 82.0K | — | — |
| Winger Dennis LDirector · 13 transactions | — | 62.8Kas of Aug 2018 | 107.0K | 5.0K | 64.3K |
| Gergel Ivan P.SVP & Chief Medical Officer · 23 transactions | — | 56.6Kas of Nov 2017 | 257.5K | — | 208.4K |
| Robin Howard WPresident & CEO, Director · 181 transactions | — | 55.1K | 5.62M | 10.0K | 4.56M |
| Kuebler Christopher ADirector · 26 transactions | — | 45.3Kas of Sep 2018 | 196.8K | — | 151.5K |
| Lingnau LutzDirector · 31 transactions | — | 35.8Kas of Sep 2020 | 249.8K | — | 215.5K |
| Ajer Jeffrey RobertDirector · 15 transactions | — | 34.2Kas of Sep 2023 | 63.3K | — | 29.1K |
| Brainard DianaDirector · 2 transactions | — | 28.6Kas of Sep 2022 | 28.6K | — | — |
| Curet MyriamDirector · 5 transactions | — | 27.4Kas of Sep 2023 | 20.4K | — | 12.2K |
| Eastham KarinDirector · 6 transactions | — | 23.2Kas of Sep 2022 | 44.5K | — | 21.3K |
| Wilson Mark AndrewChief Legal Officer · 33 transactions | — | 21.6K | 425.6K | — | 169.6K |
| Wang SusanDirector · 17 transactions | — | 20.0Kas of Nov 2015 | 135.0K | — | 115.0K |
| Myriam CuretDirector · 4 transactions | — | 19.2Kas of Dec 2020 | 29.9K | — | 1.6K |
| Zalevsky JonathanChief R&D Officer · 47 transactions | — | 15.4K | 551.1K | — | 456.2K |
| Bansal AjayFormer CFO · 15 transactions | — | 10.2Kas of Mar 2006 | 10.3K | — | 5.2K |
| Brown Michael A/CADirector · 3 transactions | — | 10.0Kas of Nov 2008 | 15.0K | — | — |
| Lerner IrwinDirector · 2 transactions | — | 10.0Kas of Nov 2008 | 10.0K | — | — |
| Ghosh RinkoChief Business Officer · 1 transaction | — | 9.8Kas of Mar 2011 | 1.1K | — | — |
| Johnston DavidSVP, Research & Development · 3 transactions | — | 6.6Kas of May 2007 | 6.5K | — | — |
| Drapeau LouisSr. VP Finance, CFO · 6 transactions | — | 6.0Kas of May 2007 | 1.0K | 5.0K | — |
| Elam Nevan CSVP, Head Pulmonary Bus. Unit · 1 transaction | — | 1.4Kas of May 2007 | 1.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -10.28M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.